Prevention & lipidsResearch article
Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future
- Narrative review
Study context
- Population
- Patients with prior major atherosclerotic cardiovascular disease (ASCVD) event, atherosclerosis without prior major ASCVD event, or diabetes
Main finding
As reported in the abstract
Major adverse CV outcomes with monoclonal antibody PCSK9 inhibitors (CV outcomes trials)
- Monoclonal antibody PCSK9 inhibitors reduce the risk of major adverse CV outcomes across a broad range of patients (prior major ASCVD event, atherosclerosis without prior major ASCVD event, diabetes)
- Clinical benefit of lowering LDL cholesterol to ∼1 mmol/L (∼40 mg/dL)
Further findings
New members of the class under study
- Oral inhibitors, RNA interference and gene therapy
Original publication
Proprotein convertase subtilisin/kexin Type 9 inhibitors: past, present, and future. Eur Heart J. Published 17 March 2026. doi:10.1093/eurheartj/ehag148
Summarised from the published abstract; every number is checked against it